Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) — Comprehensive Disease Characteristics Report

Target disease: Arrhythmogenic right ventricular cardiomyopathy MONDO ID: MONDO:0016587 · Category: Mendelian (autosomal dominant, desmosomal) Investigation: 5 iterations · 20 confirmed findings · 81 papers reviewed

Summary

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited myocardial disease defined by progressive fibrofatty replacement of the ventricular myocardium — classically the right ventricle — that creates an electrically unstable substrate producing ventricular arrhythmias, heart failure, and sudden cardiac death (SCD), especially in young people and endurance athletes. It is fundamentally a disease of the cardiac desmosome: pathogenic loss-of-function variants in desmosomal genes account for the majority of cases, with PKP2 (plakophilin-2) the single most common cause, followed by DSP, DSG2, DSC2, and JUP, plus important non-desmosomal causes including TMEM43, PLN, and FLNC. Desmosomal gene variants account for 67.4% of ARVC cases in cohort studies and 96.1% of pathogenic variants in ClinVar (PMID: 42366226).

Mechanistically, destabilization of the intercalated disc triggers a convergent signaling cascade: activation of the Hippo pathway (Merlin/NF2 → MST1/2 → LATS1/2 → YAP phosphorylation), suppression of canonical Wnt/β-catenin signaling via nuclear plakoglobin/YAP–β-catenin sequestration, and engagement of TGF-β signaling — together driving a pro-adipogenic, pro-fibrotic transcriptional program. A shared, mutation-agnostic downstream feature is downregulation of the gap-junction protein connexin-43 (Cx43), which contributes to arrhythmogenesis independent of the causal gene. Increasingly, ARVC is also recognized as an inflammatory cardiomyopathy with episodic "hot phases" that mimic myocarditis. The key environmental modifier is endurance/high-intensity exercise, which accelerates penetrance and arrhythmic risk in a dose-dependent manner and largely explains the observed male predominance.

Clinically, ARVC has a prevalence of ~1:2,000 to 1:5,000, presents typically between the second and fourth decades of life, and is diagnosed by the multiparametric 2010 modified Task Force Criteria and 2020 Padua criteria integrating imaging, ECG, tissue, arrhythmia, and genetic data. Management is currently palliative: exercise restriction, beta-blockers and antiarrhythmics, catheter ablation, and ICD implantation guided by the 2019 ARVC risk calculator, with heart transplantation reserved for end-stage disease. A new generation of AAV-based gene therapies — PKP2 gene replacement (LX2020) and mutation-agnostic Cx43 restoration — show strong preclinical efficacy and represent the first potentially disease-modifying treatments.

1. Disease Information

ARVC is an inherited cardiomyopathy characterized by progressive fibrofatty replacement of ventricular myocardium, ventricular arrhythmias, and increased sudden cardiac death risk. It was originally called arrhythmogenic right ventricular dysplasia (ARVD), later broadened to arrhythmogenic cardiomyopathy (ACM) to encompass left-dominant and biventricular forms; the 2023 ESC guidelines reintroduced "ARVC" specifically for fibrofatty right ventricular disease while using "non-dilated left ventricular cardiomyopathy" for left-sided phenotypes (PMID: 39980788).

Key identifiers: - MONDO: MONDO:0016587 - OMIM: ARVD1 (107970, TGFB3), ARVD2 (600996, RYR2), ARVD5 (604400, TMEM43), ARVD8 (607450, DSP), ARVD9 (609040, PKP2), ARVD10 (610193, DSG2), ARVD11 (610476, DSC2), ARVD12 (611528, JUP) - Orphanet: ORPHA:247 - ICD-10: I42.8 · ICD-11: BC43.3 · MeSH: D019571 (Arrhythmogenic Right Ventricular Dysplasia)

Synonyms/alternative names: arrhythmogenic right ventricular dysplasia (ARVD), arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D), arrhythmogenic cardiomyopathy (ACM), right ventricular cardiomyopathy. Left-predominant forms are termed arrhythmogenic left ventricular cardiomyopathy (ALVC).

Information source: Data are derived from aggregated disease-level resources (OMIM, Orphanet, ClinVar), disease registries (Johns Hopkins ARVC Registry, Utrecht, SHaRe, Scandinavian cohorts), and clinical/pathology studies rather than individual EHR-level extraction.

2. Etiology

Disease Causal Factors

The primary cause of ARVC is genetic, predominantly heterozygous loss-of-function variants in genes encoding the cardiac desmosome — the cell–cell adhesion junction of the intercalated disc. Desmosomal gene variants are predominant, "accounting for 67.4% of cases in cohort studies and 96.1% of pathogenic variants in ClinVar" (PMID: 42366226). Non-desmosomal genetic causes include TMEM43, PLN, FLNC, LMNA, SCN5A, DES, and RBM20 (PMID: 34970070).

Genetic Risk Factors

• Causal genes: PKP2 (most common), DSP, DSG2, DSC2, JUP, TMEM43, PLN, FLNC.
• Founder/high-penetrance variants: TMEM43 p.S358L (fully penetrant, Newfoundland founder); PKP2 Q59L (Finnish founder, ~20% penetrance).
• Modifier effect of multiple variants: carriers of >1 mutation (~4%) have earlier VT/VF (28±12 yr) and worse outcomes (PMID: 25616645).

Environmental Risk Factors

• Endurance/high-intensity exercise is the dominant modifier: "intense exercise may accelerate the phenotypic expression and the propensity to ventricular arrhythmias in patients with ACM" (PMID: 40470644).
• Male sex and age are associated with worse arrhythmic outcomes, but much of the sex effect is mediated by higher exercise dose in men (PMID: 33829244).
• Family history of ARVC/SCD.

Protective Factors

• Exercise restriction reduces arrhythmic risk and slows phenotypic progression — the primary modifiable protective intervention.
• No well-established protective genetic variants have been defined for ARVC. Non-carrier status among relatives in cascade screening is effectively protective.

Gene–Environment Interactions

The exercise–genotype interaction is the paradigmatic GxE relationship in ARVC. Mechanical load from endurance exercise stresses an already compromised desmosome, accelerating fibrofatty remodeling and arrhythmia. In a longitudinal cohort, male sex marked arrhythmia risk (OR 2.6) but lost significance after adjusting for exercise dose, indicating exercise mediates much of the sex difference (PMID: 33829244).

3. Phenotypes

ARVC symptoms typically emerge from the second to fourth decade of life (PMID: 25894016). The disease is progressive and often episodic (with arrhythmic and inflammatory "hot phase" flares).

In a tertiary cohort, "patients in the definite group were more symptomatic, with palpitations (57% vs. 17%), syncope (35% vs. 6%) and shortness of breath (28% vs. 5%, p < 0.001). T-wave inversion in V1-V3 and epsilon waves were observed only in the definite group" (PMID: 36635648).

Severity/progression: Variable and progressive; ranges from a "concealed phase" (arrhythmic risk without overt structure) to end-stage biventricular failure. In a Brazilian cohort, 5-year cumulative life-threatening arrhythmic event (LTAE) probability was 30% and HF-death/heart transplant 10% (PMID: 36720007).

Quality of life: Impaired by arrhythmia burden, ICD shocks, exercise restriction (particularly affecting athletes), heart-failure symptoms, and the psychological burden of SCD risk and cascade family screening. Formal EQ-5D/SF-36 disease-specific data were not identified in this investigation.

4. Genetic / Molecular Information

Causal Genes and Genotype–Phenotype Correlations

Variant Classification and Type

Variants are classified per ACMG/AMP guidelines (pathogenic, likely pathogenic, VUS). Most are truncating/loss-of-function (frameshift, nonsense, splice-site) — e.g., the PKP2 spectrum reported "5 frameshift, 2 nonsense, 2 splicing, 1 missense variants" (PMID: 34191271) — with important missense exceptions such as TMEM43 p.S358L. NGS panels in inherited heart disease clinics carry high VUS rates (~54%) (PMID: 39009076). Pathogenicity hotspots localize to critical domains (PKP2 ARM7/ARM8; DSG2 N-terminal cadherin repeats), whereas incidentally identified variants distribute like background population variation (PMID: 30985088).

Allele Frequency and Penetrance

ARVC-associated desmosomal variants are surprisingly prevalent in the general population but with reduced penetrance. In a Finnish cohort (n=6,334), "the collective prevalence of all 5 mutations... was 31 of 6,334 individuals, or 0.5%. The apparent founder mutation PKP2 Q59L is present in 0.3% of Finns and was previously shown to have an approximately 20% disease penetrance" (PMID: 21397041) — roughly 1 in 200 Finns carries a desmosomal variant.

Origin and Functional Consequences

Variants are germline. Functional consequence is predominantly loss of function / haploinsufficiency of desmosomal adhesion, with some dominant-negative effects. Endomyocardial samples of a DSG2 deletion carrier showed reduced immunoreactive signal for desmoglein-2, plakophilin-2, plakoglobin, and desmoplakin — indicating collective destabilization of the desmosomal complex (PMID: 21397041).

Modifier Genes, Epigenetics, Chromosomal

Carriage of a second variant modifies severity (PMID: 25616645). Epigenetic regulation involves tissue microRNAs: "miR-21-5p and miR-29b-3p are associated with fibrosis and extracellular matrix remodeling, whereas miR-133a-b and miR-130a are linked to cardiomyocyte integrity loss and desmosomal dysfunction" (PMID: 42353884); miR-217-5p, miR-708-5p, miR-135b link to Wnt/β-catenin and Hippo. No recurrent large-scale chromosomal abnormalities cause ARVC, though structural deletions (e.g., DSG2) occur.

5. Environmental Information

• Environmental factors: No environmental toxin or radiation exposure causes ARVC. The dominant non-genetic factor is mechanical/hemodynamic load from exercise.
• Lifestyle factors: Endurance and high-intensity/competitive sport is the principal lifestyle modifier — accelerating penetrance and arrhythmia; ARVC is among the most common causes of SCD in athletes (PMID: 40470644; PMID: 42305082).
• Infectious agents: None cause ARVC. However, desmosomal cardiomyopathy can present as myocarditis-like "hot phases" (most commonly DSP) with troponin release mimicking acute myocarditis, involving NLRP3-inflammasome activation and anti-desmosomal/anti-intercalated-disc autoantibodies (PMID: 41448261). This aseptic intracellular inflammation is frequently misdiagnosed as viral myocarditis, particularly in children (PMID: 41255689).

6. Mechanism / Pathophysiology

Core Causal Chain

Desmosomal LOF variant (PKP2/DSP/DSG2/DSC2/JUP)
        │
        ▼
Intercalated disc destabilization  →  ↓ Connexin-43 (Cx43) gap junctions
        │                                       │
        ▼                                       ▼
Plakoglobin translocates to nucleus     Slowed conduction, Na-current↓
        │                                (arrhythmogenic substrate)
        ▼
Hippo activation (Merlin/NF2→MST1/2→LATS1/2→YAP-P)
        │
        ▼
YAP-P + phospho-β-catenin sequestered  →  ↓ canonical Wnt/β-catenin, ↓TEAD
        │
        ▼
Pro-adipogenic + pro-fibrotic transcription  (+ DSC2→TCF7→TGF-β2 in fibroblasts)
        │
        ▼
FIBROFATTY REPLACEMENT of myocardium  →  VT/VF, SCD, heart failure
        │
   (accelerated by exercise; amplified by inflammation/autoantibodies)

Molecular Pathways

Multiple independent reviews converge on canonical and non-canonical WNT signaling, the Hippo-YAP pathway, and TGF-β signaling as the central dysregulated pathways: "these pathways include canonical and non-canonical WNT signalling, the Hippo-Yes-associated protein (YAP) pathway and transforming growth factor-β signalling" (PMID: 31028357). "Imbalance in the Wnt/β-catenin signaling and also in the crosslinked Hippo pathway leads to the transcription of proadipogenic and profibrotic genes" (PMID: 36289882). Experimentally, "altered protein constituents of intercalated discs were associated with activation of the upstream Hippo molecules" (PMID: 24276085). A distinct fibrosis arm operates through DSC2: "DSC2 deficiency upregulated transcription factor 7 (TCF7) expression, promoting its binding to TGF-β2 promoter regions to enhance TGF-β2 transcription in cardiac fibroblasts" (PMID: 42366226).

Shared Mutation-Agnostic Defect: Cx43

"The reduction in expression of the ventricular gap junction protein Cx43 (connexin-43) is a common molecular alteration underlying desmosomal junctional deficits and arrhythmias" (PMID: 41582809) — making Cx43 both a unifying mechanism and a therapeutic target.

Cellular Processes

• Cardiomyocyte death (apoptosis/necrosis) → replacement fibrosis.
• Fibro-adipogenic differentiation of cardiac progenitor/interstitial cells.
• Microtubule detyrosination: PKP2 loss increases microtubule detyrosination and membrane stiffness, reducing sodium current; parthenolide rescues both (PMID: 42366968).
• Inflammation: ACM is increasingly framed as an inflammatory cardiomyopathy — desmosomal variants activate NFκB and GSK3β signaling, promoting cytokine release and immune infiltration that may precede structural change (PMID: 42193878).

Immune / Autoantibody Involvement

"Three pathogenic ACM-IgGs activated GSK-3β upstream of p38MAPK, leading to phosphorylation and junctional loss of β-catenin. GSK-3β inhibition rescued the loss of cell cohesion" (PMID: 42219531) — establishing a pathogenic autoantibody/GSK-3β axis and a druggable node.

Single-cell / Molecular Profiling

Single-nucleus RNA-seq of left-dominant ACM hearts (5 ACM vs 4 donors) "revealed an increased proportion of fibroblasts and adipocytes in the left ventricles of LACM patients, suggesting a cellular basis for the fibrofatty remodeling observed in the disease," plus a disease-associated cardiomyocyte subpopulation (CM1) upregulating fibrosis/metabolism/stress markers (PMID: 40383406).

Suggested ontology terms: GO:0016055 (Wnt signaling), GO:0035329 (Hippo signaling), GO:0007179 (TGF-β receptor signaling), GO:0007507 (heart development), GO:0050900 (leukocyte migration); CL:0000746 (cardiac muscle cell), CL:0000057 (fibroblast), CL:0000136 (adipocyte).

7. Anatomical Structures Affected

Organ level: The heart (UBERON:0000948), primarily the right ventricle (UBERON:0002080); secondary/left ventricle (UBERON:0002084) in biventricular and left-dominant variants. Body system: cardiovascular (UBERON:0004535).

"Triangle of dysplasia": Structural remodeling primarily involves three RV regions — "the three regions ('ARVC triangle') primarily involved in ARVC structural remodeling": RV inflow/subtricuspid region, RV outflow tract, and RV apex (PMID: 33927217). Ex vivo 9.4T MRI showed high fat content in these regions: "the healthy heart exhibited twice less fat than the ARVC heart (31.9%, 28.7% and 1.3% of fat in the same regions, respectively)," histologically confirmed, with fibrosis also present in fat-poor areas (PMID: 33927217).

Tissue/cell level: Cardiac muscle tissue is replaced by fibrous (connective) and adipose tissue. Cell populations: cardiomyocytes (CL:0000746, lost), fibroblasts (CL:0000057, expanded), adipocytes (CL:0000136, expanded) (PMID: 40383406).

Subcellular level: The intercalated disc / desmosome (GO:0030057 desmosome; GO:0005912 adherens junction), gap junction (GO:0005921), nucleus (plakoglobin/YAP translocation; increased nuclear stiffness in TMEM43 carriers), and cytoskeleton/microtubules (GO:0005874).

Progression pattern: Fibrofatty replacement typically advances from epicardium/mid-myocardium toward endocardium. Left-dominant/biventricular variants involve LV lateral/posterior basal segments — "cardiac magnetic resonance showed LV late gadolinium enhancement in the LV lateral and posterior basal segments in all patients" (PMID: 33197325).

Lateralization: RV-dominant (classic), LV-dominant (ALVC), or biventricular.

8. Temporal Development

• Onset: Usually adolescence to adulthood (2nd–4th decades) (PMID: 25894016); pediatric-onset ARVD occurs (mean 12±4 yr) and may be misdiagnosed as myocarditis (PMID: 31375646). Late presentation (≥50 yr) occurs in ~21% and is not benign — 65% sustained VA over 6 years (PMID: 28215569).
• Onset pattern: Insidious/chronic, punctuated by acute arrhythmic or inflammatory ("hot phase") episodes.
• Disease stages: (1) Concealed phase — arrhythmic risk with subtle/absent structure; (2) Overt electrical disease — symptomatic arrhythmias, ECG changes, structural RV abnormality; (3) RV failure; (4) Biventricular/end-stage failure.
• Progression rate: Variable, generally slowly progressive over decades; accelerated by exercise.
• Course pattern: Progressive with episodic arrhythmic/inflammatory flares.
• Duration: Chronic, lifelong.
• Critical periods: Adolescence/young adulthood coincident with sport participation is the critical window for SCD and for intervention (exercise restriction, ICD).

9. Inheritance and Population

• Prevalence: ~1:2,000 to 1:5,000: "Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetic heart disease with a prevalence of 1 : 2000 to 1 : 5000" (PMID: 40202346).
• Inheritance: Predominantly autosomal dominant with reduced, age-dependent penetrance and variable expressivity. Recessive cardiocutaneous forms: Naxos disease — "mutations in the genes encoding the desmosomal proteins plakoglobin and desmoplakin have been identified as the cause of Naxos disease" (JUP; woolly hair + palmoplantar keratoderma; ~100% cardiac penetrance by adolescence — PMID: 16722579) — and Carvajal syndrome (DSP, left-dominant — PMID: 25824144).
• Penetrance: Incomplete and age-dependent — e.g., PKP2 Q59L ~20% penetrance (PMID: 21397041); by contrast TMEM43 p.S358L is fully penetrant (PMID: 24598986).
• Founder effects: TMEM43 p.S358L (Newfoundland; "an estimated age of 1300-1500 years for the mutation, which proves the European origin of the Newfoundland mutation" — PMID: 24598986); PKP2 Q59L (Finland).
• Carrier frequency: ~0.5% collective desmosomal-variant carrier prevalence (~1 in 200) in Finland (PMID: 21397041).
• Sex ratio: Male predominance. "Ventricular arrhythmia had occurred at inclusion or occurred during follow-up in 85 patients (33% of females vs. 55% of males, P = 0.002). Exercise doses were higher in males compared with females," and the sex effect lost significance after adjustment for exercise dose (PMID: 33829244); SHaRe registry showed 61% male predominance with gene-specific variation (DSP more common in females, OR 3.3) (PMID: 42159538).
• Age distribution: Clinically overt from 2nd–4th decades; a substantial minority present after 50.

10. Diagnostics

Clinical Criteria

Diagnosis uses the multiparametric 1994 Task Force Criteria, revised as the 2010 modified Task Force Criteria with quantitative structural thresholds, and updated by the 2020 Padua criteria (adding left-predominant/biventricular criteria incorporating CMR late gadolinium enhancement). "The original right-dominant phenotype is traditionally diagnosed using the 2010 task force criteria, a multifactorial algorithm divided into major and minor criteria" (PMID: 38512728); "in 2010, the task force criteria were revised to include quantitative abnormalities" (PMID: 32032135). The 2010 criteria are more specific: "Of 968 patients, 220 (22.7%) fulfilled either a major or a minor 1994 TFC, and 25 (2.6%) fulfilled any of the 2010 TFC criterion" (PMID: 24996808).

Tests

• ECG: T-wave inversion V1–V3, epsilon wave, QRS fragmentation, low precordial QRS voltage, signal-averaged ECG late potentials, LBBB-morphology VT.
• Imaging: Echocardiography and cardiac MRI (gold standard) demonstrating RV dilatation, reduced RVEF, aneurysms/regional wall-motion abnormalities, and late gadolinium enhancement; RV angiography ("pile d'assiettes" appearance) in select cases.
• Tissue: Endomyocardial biopsy showing fibrofatty replacement and reduced desmosomal immunoreactivity.
• Genetic testing: Broad cardiomyopathy/arrhythmia NGS gene panels (not limited to validated ARVC genes) are recommended; WES/WGS in select cases. Panels have ~31% diagnostic yield with ~54% VUS in ICC clinics (PMID: 39009076). "Using a broad cardiomyopathy and arrhythmia gene panel in ARVC probands, rather than limiting testing to validated ARVC genes alone, is warranted" (PMID: 42389803).
• Biomarkers: Circulating miR-15a-5p, miR-16-5p, miR-92a-3p differentiate high- vs low-risk patients (PMID: 40222719).
• Emerging: Machine-learning models (gradient-boosted trees, AUC 0.943) enhance ARVC detection from multimodal data (PMID: 41884351).

Differential Diagnosis

Idiopathic RVOT VT, myocarditis (including hot-phase overlap), cardiac sarcoidosis, Brugada syndrome, dilated cardiomyopathy, athlete's heart, and non-desmosomal phenocopies (e.g., RIT1-related) (PMID: 41918562).

Screening

First-degree relatives undergo cascade genetic + clinical screening (ECG, echo, Holter, CMR) with genetic counseling.

11. Outcome / Prognosis

• Mortality/SCD: Principal risk is SCD from ventricular arrhythmia, especially in young athletes — "ACM was the cause of SCD in 29% of athletes" in a 4-decade national juvenile registry (PMID: 42305082).
• Natural history: "The 5-year cumulative probability of LTAE was 30% and HF-death/HTx was 10%" (PMID: 36720007).
• Genotype-specific prognosis: PKP2 better prognosis (PMID: 34191271); DSG2/DSP higher HF/transplant risk; TMEM43 p.S358L malignant — "TMEM patients had worse composite endpoint of death or transplantation (60% vs. 0, P = 0.035; log-rank P = 0.013)" (PMID: 28960618).

Risk Stratification

The 2019 ARVC risk calculator estimates 5-year sustained-VA risk. Enhancers:

Other established prognostic factors: prior cardiac arrest/syncope, sustained VT, RV/LV dysfunction, extent of T-wave inversion, male sex, and young age.

12. Treatment

Current therapy is palliative — it manages arrhythmias and heart failure but does not address the molecular substrate (PMID: 41301430).

Pharmacotherapy (MAXO:0000058 pharmacotherapy)

• Beta-blockers — grade I for extrasystoles/VT: "Beta-blockers are recommended for patients with extrasystoles or ventricular tachycardia (grade I recommendation). If beta-blockers alone have an insufficient effect, amiodarone, flecainide or sotalol can be added (grade IIa)" (PMID: 40202346). Drug classes: beta-adrenergic antagonists, amiodarone (CHEBI:2663), sotalol, flecainide.
• Heart failure therapy for ventricular dysfunction.

Interventional / Device

• Catheter ablation — grade IIa for recurrent VT; palliative. Meta-analysis (24 studies, 717 patients): "acute efficacy of 89.8%, major complication of 5.2%, follow-up of 28.9 months, VT freedom of 75.3%, all-cause mortality of 1.1% and heart transplantation of 0.6%"; "epicardial ablation is associated with better long-term VT freedom" (OR 0.50 vs endocardial-only) (PMID: 33343648). DSP-ACM and TMEM43 require endo-epicardial mapping (PMID: 38206263).
• ICD (MAXO implantable cardioverter defibrillator) — grade I for SCD survivors; primary-prevention decisions guided by the ARVC risk calculator; earlier ICD reasonable for PLN/FLNC/LMNA genotypes.
• Heart transplantation (MAXO:0000384) — for end-stage HF or intractable arrhythmias.

Lifestyle

• Exercise restriction — central, because intense exercise accelerates phenotype and arrhythmia (PMID: 40470644).

Emerging / Experimental Therapies

• AAV PKP2 gene replacement (LX2020, AAVrh10): "we show minimal doses required for efficacy for AAVrh10.PKP2 (LX2020) to rescue cardiac (molecular and especially RV) deficits, arrhythmia burden and survival in PKP2 ACM mice," with no adverse events in non-human-primate safety studies (PMID: 40175378).
• Mutation-agnostic AAV-Cx43 restoration: "Administration of AAV-Cx43 (adeno-associated-viral-mediated connexin-43) gene therapy alleviated the severe biventricular dilatation, contractile dysfunction, and arrhythmias, while prolonging lifespan in 2 severe desmosomal ACM mouse models" (PMID: 41582809).
• AAV8-FGF21: mitigated structural change and adrenergic arrhythmias in PKP2-cKO mice (PMID: 41759869).
• Small molecules: parthenolide (microtubule detyrosination — PMID: 42366968); GSK-3β inhibition (autoantibody axis — PMID: 42219531); apremilast (PDE4 inhibitor; improves cardiomyocyte cohesion via plakoglobin Ser665 phosphorylation and ERK1/2 — PMID: 41185038).
• Immunomodulation during active inflammatory phases (NFκB/GSK3β/cytokine-directed) (PMID: 42193878).

Pharmacogenomics / Personalized Medicine

Genotype-guided management is emerging (e.g., earlier ICD for PLN/FLNC/LMNA; gene-specific ablation strategy) (PMID: 34970070).

13. Prevention

• Primary prevention: Exercise restriction/avoidance of competitive endurance sport in carriers; ICD in high-risk individuals.
• Secondary prevention: Cascade genetic and clinical screening of first-degree relatives with pre-/post-test genetic counseling; genotype-positive/phenotype-negative relatives receive periodic follow-up. "Pre-test and post-test counseling were provided to probands and cascade screening offered to relatives" (PMID: 39009076). Family screening is warranted even in gene-elusive ARVC — 17% of gene-elusive families harbored a P/LP variant in a different cardiomyopathy/arrhythmia gene (PMID: 42389803).
• Tertiary prevention: ICD, ablation, and HF therapy to prevent SCD and progression.
• Risk stratification: ARVC risk calculator + CMR LGE/strain + electroanatomic mapping (Section 11).
• Immunization/public health: Not applicable (non-infectious, non-communicable Mendelian disease).
• Counseling: Genetic counseling for family planning; preimplantation/prenatal testing possible for known familial variants.

14. Other Species / Natural Disease

• Taxonomy: Homo sapiens (NCBI:txid9606); naturally occurring in Canis lupus familiaris (dog, NCBI:txid9615).
• Breeds: Boxer and English bulldog dogs. "This myocardial disorder has also been described in Boxer and English bulldogs (EBs)" (PMID: 40540101). Boxer ARVC is associated with a striatin (STRN) deletion.
• Comparative pathology: Canine ACM recapitulates human ECG phenotype — in 59 EBs, ACM dogs showed wider QRS and longer terminal activation, and "the TWI and ɛ wave in ACM group were respectively present in 19% and 32%," correlating with echocardiographic RV parameters (PMID: 40540101).
• Orthologous genes: PKP2, DSP, DSG2, DSC2, JUP, TMEM43 are conserved across mammals; STRN in dogs.
• Zoonotic potential: None (genetic disease, not transmissible).

15. Model Organisms

Comprehensive reviews of intercalated-disc-gene animal models confirm that murine and hiPSC models have driven mechanistic understanding and therapeutic development (PMID: 38892395; PMID: 42137277). Limitations: murine models incompletely capture the exercise-dependent, slowly progressive, and inflammatory "hot-phase" aspects of human disease and human variant heterogeneity. Resources: MGI, IMPC, Cellosaurus, Alliance of Genome Resources, OMIA.

Mechanistic Model / Interpretation

ARVC is best understood as a desmosome-initiated, signaling-amplified, mechanically-triggered fibrofatty cardiomyopathy. The upstream event is loss of desmosomal adhesion at the intercalated disc. This has two immediate consequences that map onto the two clinical hallmarks:

1. Electrical instability (upstream, early): reduced Cx43 gap junctions and altered sodium-channel function (partly via microtubule detyrosination) slow conduction and create a re-entrant substrate — explaining why arrhythmias and SCD can precede overt structural disease (the concealed phase). This is the mutation-agnostic arrhythmia axis and the rationale for Cx43-restoration therapy.

2. Structural remodeling (downstream, progressive): nuclear translocation of plakoglobin, Hippo-YAP activation, Wnt/β-catenin suppression, and TGF-β/TCF7 engagement redirect transcription toward adipogenesis and fibrosis, producing the "triangle of dysplasia" fibrofatty replacement, RV dilatation/aneurysms, and eventually biventricular failure.

Layered on top is an inflammatory amplifier (NFκB/GSK3β, NLRP3-inflammasome, anti-DSG2 autoantibodies) that produces episodic myocarditis-like hot phases, and a mechanical accelerator (endurance exercise) that increases wall stress on an adhesion-deficient myocardium — accounting for the dose-dependent exercise effect and the male predominance mediated by exercise. Genotype tunes the phenotype: PKP2 is RV-predominant and comparatively benign; DSG2/DSP skew toward LV involvement and heart failure; TMEM43 p.S358L is fully penetrant and malignant.

Evidence Base

Limitations and Knowledge Gaps

1. Reduced penetrance and VUS burden: ~0.5% population carrier frequency with ~20% penetrance and ~54% VUS rate in panels complicate individual risk prediction and genetic counseling.
2. Gene-elusive disease: A substantial fraction of clinically definite ARVC lacks an identified pathogenic variant, limiting cascade screening in those families.
3. Risk stratification imperfection: The 2019 risk calculator underperforms in non-classical/left-dominant ACM; ringlike LGE and other markers add value but are not fully integrated.
4. Palliative therapeutics: No approved disease-modifying therapy currently exists; gene therapies remain preclinical/early-phase.
5. Causality of inflammation/autoantibodies: Whether inflammation initiates or merely amplifies disease — and whether anti-DSG2 autoantibodies are causal — remains incompletely established.
6. Quality-of-life data: Formal per-phenotype QoL instrument data (EQ-5D/SF-36) for ARVC were not identified in this investigation.
7. Model limitations: Murine models incompletely capture exercise-dependent, slowly progressive, and hot-phase human features.

Proposed Follow-up Experiments / Actions

1. Advance AAV gene therapies to clinical trials — track PKP2 replacement (LX2020) and mutation-agnostic Cx43 restoration; monitor ClinicalTrials.gov for first-in-human data.
2. Prospective validation of multimodal + ML risk models integrating CMR LGE (including ringlike pattern), FT-CMR strain, electroanatomic scar, and circulating miRNAs to improve the ARVC risk calculator, especially for left-dominant/biventricular phenotypes.
3. Test targeted small molecules (parthenolide, GSK-3β inhibitors, apremilast) and immunomodulation during hot phases in controlled preclinical and early-phase human studies.
4. Deep-phenotype gene-elusive families with WGS, structural-variant, and non-coding analyses; adopt broad cardiomyopathy/arrhythmia panels as standard.
5. Functionally reclassify VUS using hiPSC-CM and high-throughput assays to reduce diagnostic uncertainty.
6. Longitudinal exercise-dose studies to define safe activity thresholds by genotype and sex.
7. Collect standardized QoL/PROM data (EQ-5D, SF-36, ICD-specific measures) across ARVC registries.

References (selected PMIDs)

42366226, 42244336, 40202346, 25894016, 42305082, 40470644, 24276085, 34191271, 30790397, 25616645, 16722579, 21397041, 36635648, 36720007, 41582809, 42219531, 41185038, 40540101, 38512728, 32032135, 24996808, 41608798, 23392584, 40222719, 33927217, 33197325, 39009076, 42389803, 40383406, 42353884, 24598986, 28960618, 33343648, 33829244, 42159538, 31028357, 36289882, 40175378, 41759869, 42193878, 41448261, 41255689, 42366968, 38031154, 35152298, 24792740, 24515411, 28215569, 38206263, 41918562, 41884351, 34970070, 38892395, 42137277, 39980788, 25824144, 30985088, 41301430